Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 3/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31547150 | 0.80 | ALDH1A1 (0.32) | — | |
| SCHEMBL11858505 | 0.80 | ALDH1A1 (0.32) | — | |
| SCHEMBL11857778 | 0.78 | MAPT (0.32) | — | |
| SCHEMBL2299371 | 0.78 | MAPT (0.32) | — | |
| SCHEMBL7909118 | 0.78 | MAPT (0.32) | — | |
| SCHEMBL24603326 | 0.74 | ALDH1A1 (0.30) | — | |
| SCHEMBL10442623 | 0.74 | NOS3 (0.30) | — | |
| SCHEMBL3859583 | 0.74 | ALDH1A1 (0.30) | — | |
| SCHEMBL3859581 | 0.74 | ALDH1A1 (0.30) | — | |
| SCHEMBL10442622 | 0.74 | NOS3 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280798-B1 | BICYCLIC HETEROCYLCES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR PRODUCING THEM | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-01-03 | — | — | EP | disclosed |
| US-6627634-B2 | Antitumor agents, treatment of the lungs and respiratory tract | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-30 | — | — | US | disclosed |
| EP-1280798-A1 | BICYCLIC HETEROCYLCES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR PRODUCING THEM | Boehringer Ingelheim Pharma KG (DE) | 2003-02-05 | — | — | EP | disclosed |
| US-20010044435-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2001-11-22 | — | — | US | disclosed |
| WO-2001077104-A1 | BICYCLIC HETEROCYLCES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR PRODUCING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044435-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | RET, BMX, CYP11B1 | PLG 3063/4885GABRA1 558/4885GABRG2 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.